ArticleBMC pediatrics2026
Two birds, one BiTE: blinatumomab achieves concurrent B-ALL control and EBV clearance in post-HSCT patients: two cases report.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHematopoietic stem cell transplantation (HSCT) is an effective treatment for refractory or relapsed acute lymphoblastic leukemia (ALL). However, persistent challenges, such as post-transplant relapse and Epstein-Barr virus (EBV) reactivation, remain unresolved. The current standard prophylactic strategies are complex to implement and demonstrate inconsistent efficacy. Optimizing methods to prevent cancer recurrence and control viremia is crucial for enhancing patient outcomes. CASE PRESENTATION: We present two novel cases of patients with B-cell ALL who developed EBV viremia following allogeneic HSCT and received blinatumomab as a relapse prophylaxis. Both cases achieved sustained EBV eradication (for more than 3 months) following a course of blinatumomab (8 µg/day × 8 days), initiated during asymptomatic viremia at 3 months post-transplant. Both patients demonstrated favorable therapeutic outcomes.
conclusionsBlinatumomab may represent a promising therapeutic option for managing EBV viremia and providing relapse prophylaxis in patients with B-cell ALL following allogeneic HSCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.